◀ Back to MTOR

EGFR — MTOR

Pathways - manually collected, often from reviews:

• NCI Pathway Database EGFR-dependent Endothelin signaling events: EGF/EGFR dimer/SHC/GRB2/SOS1 complex (EGF-EGFR-SHC1-GRB2-SOS1) → mTOR (MTOR) (modification, activates) Iwasaki et al., Endocrinology 1999
  Evidence: mutant phenotype, other species

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Biogrid Interaction: EGFR — MTOR (physical association, affinity chromatography technology) Foerster et al., Proteomics 2013

Text-mined interactions from Literome

Rao et al., Neoplasia (New York, N.Y.) 2005 (Glioblastoma) : Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells
Fan et al., Cancer Res 2007 (Glioma) : These experiments show that a dual inhibitor of PI3Kalpha and mTOR augments the activity of EGFR blockade, offering a mechanistic rationale for targeting EGFR, PI3Kalpha, and mTOR in the treatment of EGFR-driven, PTEN-mutant glioma
Cao et al., Cell Signal 2008 : Inhibition of EGFR also suppresses UV-induced activation of PI3K/AKT/mTOR/S6K and NF-kappaB signal transduction pathways
Reardon et al., J Neurooncol 2010 (Central Nervous System Neoplasms...) : We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor , plus sirolimus, an inhibitor of the mammalian target of rapamycin , among patients with recurrent glioblastoma ( GBM ) in a phase 2, open-label, single-arm trial
Schmid et al., Br J Cancer 2010 (Lung Neoplasms...) : In this report we investigated the combination of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathway inhibition as a possible new therapeutic strategy for small cell lung cancer ( SCLC )
He et al., Ann Oncol 2012 (Breast Neoplasms...) : Human epidermal growth factor receptor ( HER2 ), insulin receptor and IGF-I receptor involve the same PI3K/AKT/mTOR signaling , and different antidiabetic pharmacotherapy may differentially affect this pathway, leading to different prognoses of HER2+ breast cancer
Blakeley et al., Curr Opin Otolaryngol Head Neck Surg 2012 (Neovascularization, Pathologic...) : Inhibition of angiogenesis as well as regulation of mammalian target of rapamycin and the epidermal growth factor receptor family of receptors are the focus of current clinical investigations
Wang et al., PloS one 2013 : The parallel increase of AKT ( S473 ) and EGFR ( T1068 ) in the cells following PP242 treatment raised the possibility that EGFR phosphorylation might contribute to the PP242 incomplete inhibition of mTORC2